M
Mirus
Focused on the design of innovative solutions for the treatment of spinal and orthopaedic degeneration and deformities
About Mirus
MiRus is a pioneering medical technology startup that operates in the cardiovascular and orthopaedic sectors. The company's mission is to improve the lives of patients suffering from these diseases by making surgeries less invasive and implants safer and more durable. MiRus' unique selling proposition lies in its proprietary Rhenium-based alloy, MoRe®, inspired by the material science used in NASA's rocket engines.
Read full description
This alloy has been developed over 15 years and is used to create innovative implant designs and novel procedural solutions. MoRe® is significantly superior to traditional medical alloys like Titanium and Cobalt Chromium, being stronger, more fatigue resistant, and more biofriendly. It also generates lower levels of metal ions in tissue, reducing potential complications.
MiRus has launched a line of transformational MoRe® implants that are smaller, more durable, and biologically superior to existing options. The company also offers advanced remote monitoring systems to improve patient outcomes over the continuum of care.
MiRus' business model is based on the development and sale of these advanced medical implants and procedural solutions. The company serves a broad range of clients, including hospitals, clinics, and healthcare providers, who are looking for innovative and safer solutions for their patients.
As an early-stage company, MiRus was founded by a team of experienced entrepreneurs with a track record of creating disruptive technologies and highly valued companies. The company offers career development opportunities based on individual strengths and potential, indicating a strong focus on talent acquisition and retention.
At a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Marietta, United States
- Employees
- 130
- Open positions
- 2
- Dealroom signal
- 87.6/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, medical implants, Cardiology and cardiovascular, Orthopedic, Verified Unicorns and $1B Exits, Tech for Hospitals and Clinics, DT and LS, science-based
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Mirus.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | May 2026 | $1.5B | $4.4B | Boston Scientific | ↗ |
| LATE VCOther financing | Jul 2021 | $65M | $260M | Mammoth Scientific | — |
Growth signals
Latest recorded traffic for Mirus is 5.2K monthly website visits, up 48.6% over the last three months. Mirus's team grew 2.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Mammoth Scientific
Boston Scientific
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mirus on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mirus’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.